GlaxoSmithKline has announced that the U.S. Food and Drug Administration
granted a priority review for Hycamtin, as a treatment for advanced cervical cancer that has not been cured by surgery
or radiation therapies. Currently, Hycamtin is administered in the treatment of metastatic ovarian and lung cancer. The
priority review means that the drug could be approved in the treatment for advanced cervical cancer in as little as six
months. In the United States, cervical cancer is the third most common gynecological cancer among women, with close to
12,000 new cases diagnosed annually. For more information on advanced cervical cancer, Relapsed Ovarian Cancer, is a booklet
offered as a PDF download.
Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!
